Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC schedule

This article was originally published in The Tan Sheet

Executive Summary

Previously announced tentative meeting date in March has been cancelled, according to FDA. Still on the calendar is a meeting in June with the day yet to be announced. Preliminary meeting dates for 2004 appeared in Federal Register late last year (1"The Tan Sheet" Jan. 12, 2004, In Brief)...

You may also be interested in...



FDA Advisory committee schedule

FDA's Nonprescription Drugs Advisory Committee is slated for meetings in March and June, with specific dates to be announced, according to a tentative schedule of advisory committee meetings published in the Dec. 31 Federal Register. Possible overlaps with other committees may include the Endocrinologic & Metabolic Drugs Advisory Committee, slated to meet June 22-23, the Dermatologic & Ophthalmic Drugs Advisory Committee (June 24-25) and the Pulmonary-Allergy Drugs Advisory Committee, scheduled for June 29-30...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Topics

UsernamePublicRestriction

Register

PS096513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel